Arena Pharmaceuticals, Inc. (ARNA)
Stock Price:
$64.68 USD
-0.15 (-0.23%)
Updated November 23, 4:00 PM EST - Market closed
After-hours: $64.60 -0.08 (-0.12%) Nov 23, 7:52 PM
Key Info
| Market Cap |
3.76B |
| Revenue (ttm) |
3.28M |
| Net Income (ttm) |
-370.88M |
| Shares Out |
58.16M |
| EPS (ttm) |
-7.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 23 |
| Last Price |
$64.68 |
| Previous Close |
$64.83 |
| Change ($) |
-0.15 |
| Change (%) |
-0.23% |
| Day's Open |
64.94 |
| Day's Range |
63.83 - 65.46 |
| Day's Volume |
530,148 |
| 52-Week Range |
32.95 - 90.19 |
More Stats
| Market Cap |
3.76B |
| Enterprise Value |
2.64B |
| Earnings Date (est) |
Mar 2, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
58.16M |
| Float |
57.95M |
| EPS (basic) |
-7.09 |
| EPS (diluted) |
-7.04 |
| FCF / Share |
-5.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.63M |
| Short Ratio |
5.22 |
| Short % of Float |
6.26% |
| Beta |
1.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,145.57 |
| PB Ratio |
3.22 |
| Revenue |
3.28M |
| Operating Income |
-385.21M |
| Net Income |
-370.88M |
| Free Cash Flow |
-310.71M |
| Net Cash |
1.12B |
| Net Cash / Share |
19.28 |
| Gross Margin |
17,507.16% |
| Operating Margin |
-11,729.93% |
| Profit Margin |
-11,293.70% |
| FCF Margin |
-9,461.30% |
| ROA |
-19.13% |
| ROE |
-32.03% |
| ROIC |
-42.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (14)
| Buy |
14 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$94.79*
(46.55% upside)
Low
76.0
Current: $64.68
High
116.0
Target: 94.79
*Average 12-month price target from 14 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 806 | 17.97 | 21.34 | 92.16 | 13.40 | 36.97 | 81.39 | 27.59 | 12.72 | 16.61 |
| Revenue Growth | 4387.65% | -15.78% | -76.85% | 587.89% | -63.76% | -54.58% | 195.04% | 116.9% | -23.44% | - |
| Gross Profit | 806 | 17.97 | 21.34 | 92.16 | 13.40 | 29.21 | 75.21 | 23.92 | 4.62 | 9.20 |
| Operating Income | 483 | -145 | -91.97 | -5.26 | -104 | -105 | -22.94 | -57.11 | -82.80 | -96.36 |
| Net Income | 398 | -29.40 | -91.41 | -22.52 | -108 | -60.51 | -19.44 | -85.48 | -109 | -125 |
| Shares Outstanding | 49.78 | 47.04 | 32.99 | 24.31 | 24.07 | 21.97 | 21.81 | 19.65 | 13.92 | 10.96 |
| Earnings Per Share | 7.69 | -0.63 | -2.77 | -0.93 | -4.49 | -2.80 | -0.90 | -4.50 | -8.00 | -11.40 |
| Operating Cash Flow | 569 | -132 | -66.64 | -61.48 | -98.11 | -101 | 72.80 | -44.05 | -78.26 | -52.32 |
| Capital Expenditures | -4.82 | -0.69 | 0.68 | 0.14 | 1.11 | -8.86 | -9.10 | -1.75 | -0.59 | -4.16 |
| Free Cash Flow | 564 | -133 | -65.97 | -61.34 | -97.00 | -110 | 63.70 | -45.79 | -78.84 | -56.48 |
| Cash & Equivalents | 740 | 446 | 247 | 90.71 | 156 | 163 | 222 | 156 | 57.63 | 151 |
| Total Debt | 49.43 | 52.71 | 61.75 | 65.27 | 68.25 | 70.74 | 72.79 | 74.46 | 90.47 | 125 |
| Net Cash / Debt | 690 | 393 | 185 | 25.45 | 87.94 | 92.47 | 149 | 81.63 | -32.84 | 25.76 |
| Assets | 1,174 | 687 | 339 | 169 | 257 | 276 | 340 | 261 | 157 | 266 |
| Liabilities | 103 | 80.65 | 132 | 129 | 203 | 229 | 248 | 163 | 147 | 186 |
| Book Value | 1,071 | 606 | 207 | 39.90 | 53.54 | 47.35 | 91.86 | 98.64 | 10.56 | 80.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arena Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
320 |
| CEO |
Amit Dilip Munshi |
Stock Information
| Ticker Symbol |
ARNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARNA |
| IPO Date |
July 28, 2000 |
Description
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Company and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.